JPRN-UMIN000006372已完成未知
Phase II study of Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy for maintenance of Patients With Neovascular Maculopathy - Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy(Phase II)
Department of Ophthalmology, Osaka University Medical School0 个研究点目标入组 120 人开始时间: 2011年9月20日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 40years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Pregnancy(woman of childbearing potential:Refusal or inability to use effective means of contraception) Breast feeding Active or uncontrolled infection Unhealed external wound Concurrent treatment with steroids or immunosuppressing agent Uncontrolled brain and/or intraspinal lesion(s) Decision of unsuitableness by principal investigator or physician-in-charge.
研究者
相似试验
终止
1 期
Pilot Study of partially Human Leucocyte Antigen (HLA)-mismatched stem cell infusions after chemotherapy for acute myeloid leukaemia in patients over the age of 60.ACTRN12613000337774St Vincent's Hospital, Sydney12
撤回
2 期
A phase I/II *minor histocompatibility antigen UTA2-1 loaded, PD-L silenced Dendritic cell vaccination trial after allogeneic Stem Cell Transplantation to improve the safety and efficacy of Donor Lymphocyte Infusions.hematological B cell malignancies blood cell cancer10027656NL-OMON43853Vrije Universiteit Medisch Centrum12
进行中（未招募）
不适用
Donor Dendritische Cellen vaccinatie bij hematologische maligne aandoeningeEUCTR2012-002435-28-NLniversity Medical Center Utrecht
已完成
2 期
A phase I/II *minor histocompatibility antigen (mHag)-based Dendritic cell (DC) vaccination trial after allogeneic Stem Cell Transplantation (allo-SCT) to improve the safety and efficacy of donor lymphocyte infusions.bone marrow and lymphatic organscancers of the bloodhematological malignacy10035227NL-OMON37500niversitair Medisch Centrum Utrecht30
招募中
2 期
AML-SCT15acute myeloid leukemia (AML)JPRN-jRCTs051180190YABE Hiromasa66